Antibody conjugates and therapeutic strategies

Paul McCarron; S. A. Olwill; W. M. Y. Marouf; R. J. Buick; B. Walker; C. J. Scott

Antibody conjugates and therapeutic strategies

Paul McCarron
, S. A. Olwill
, W. M. Y. Marouf
, R. J. Buick
, B. Walker
, C. J. Scott

Research output: Contribution to journal › Article › peer-review

Abstract

Immunotherapeutics represent the largest group of molecules currently in development as new drug entities. These versatile molecules are being investigated for the treatment of a range of pathological conditions including cancer, infectious and inflammatory diseases. Antibodies can be used to exert biological effects themselves or as delivery agents of conjugated drug molecules. Site-specific delivery of therapeutic agents has been an ultimate goal of the pharmaceutical industry in order to maximize drug action and minimize side effects. Antibodies have the potential to realize this objective and in this review we will examine some of the main strategies currently being employed for the development of these diverse therapeutic molecules.

Original language	English
Pages (from-to)	368-380
Journal	Molecular Interventions
Volume	5
Issue number	6
Publication status	Published (in print/issue) - 2005

Bibliographical note

PT: J; TC: 9

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@article{555af3ae64644915b82d1e9cd9299755,

title = "Antibody conjugates and therapeutic strategies",

abstract = "Immunotherapeutics represent the largest group of molecules currently in development as new drug entities. These versatile molecules are being investigated for the treatment of a range of pathological conditions including cancer, infectious and inflammatory diseases. Antibodies can be used to exert biological effects themselves or as delivery agents of conjugated drug molecules. Site-specific delivery of therapeutic agents has been an ultimate goal of the pharmaceutical industry in order to maximize drug action and minimize side effects. Antibodies have the potential to realize this objective and in this review we will examine some of the main strategies currently being employed for the development of these diverse therapeutic molecules.",

author = "Paul McCarron and Olwill, \{S. A.\} and Marouf, \{W. M. Y.\} and Buick, \{R. J.\} and B. Walker and Scott, \{C. J.\}",

note = "PT: J; TC: 9",

year = "2005",

language = "English",

volume = "5",

pages = "368--380",

journal = "Molecular Interventions",

issn = "1543-2548",

publisher = "American Society for Pharmacology and Experimental Therapeutics",

number = "6",

}

TY - JOUR

T1 - Antibody conjugates and therapeutic strategies

AU - McCarron, Paul

AU - Olwill, S. A.

AU - Marouf, W. M. Y.

AU - Buick, R. J.

AU - Walker, B.

AU - Scott, C. J.

N1 - PT: J; TC: 9

PY - 2005

Y1 - 2005

N2 - Immunotherapeutics represent the largest group of molecules currently in development as new drug entities. These versatile molecules are being investigated for the treatment of a range of pathological conditions including cancer, infectious and inflammatory diseases. Antibodies can be used to exert biological effects themselves or as delivery agents of conjugated drug molecules. Site-specific delivery of therapeutic agents has been an ultimate goal of the pharmaceutical industry in order to maximize drug action and minimize side effects. Antibodies have the potential to realize this objective and in this review we will examine some of the main strategies currently being employed for the development of these diverse therapeutic molecules.

AB - Immunotherapeutics represent the largest group of molecules currently in development as new drug entities. These versatile molecules are being investigated for the treatment of a range of pathological conditions including cancer, infectious and inflammatory diseases. Antibodies can be used to exert biological effects themselves or as delivery agents of conjugated drug molecules. Site-specific delivery of therapeutic agents has been an ultimate goal of the pharmaceutical industry in order to maximize drug action and minimize side effects. Antibodies have the potential to realize this objective and in this review we will examine some of the main strategies currently being employed for the development of these diverse therapeutic molecules.

M3 - Article

SN - 1543-2548

VL - 5

SP - 368

EP - 380

JO - Molecular Interventions

JF - Molecular Interventions

IS - 6

ER -

Antibody conjugates and therapeutic strategies

Abstract

Bibliographical note

UN SDGs

Fingerprint

Cite this